InvestorsHub Logo
Followers 62
Posts 7542
Boards Moderated 1
Alias Born 01/02/2003

Re: johngnatt post# 322946

Tuesday, 02/02/2021 7:23:57 AM

Tuesday, February 02, 2021 7:23:57 AM

Post# of 425653
John...QUOTE " if Icosapent ethyl prescriptions sky rocket beyond what is considered the competing market for >500 indication, they are being complicit in supplying the generic for an indication they are not approved for....Please dig holes in this logic"

I agree with your logic.

Amarin has initiated suit against Healthnet and Hickma because they have knowledge of the total volumes of Icosapent ethyl prescriptions being sold to patients and the indications for which it is being used... and they have conspired to flout the U.S. patent office, the FDA and the Nevada court.











Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News